ABSCF (AB Science) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABSCF AB Science ABSCF
60 GF Score
Price $1.12
GF Value $1.39
Valuation Modestly Undervalued
! 11 Warning Signs
View Full Analysis

What is AB Science SpecialCharges?

Special Charges only applies to banks.

ABSCF
60GF Score
AB Science ABSCF
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AB Science (ABSCF) Overvalued in 2026?

Based on GuruFocus' analysis, AB Science stock appears to be undervalued. The current stock price of $1.12 is trading 19.4% below its estimated GF Value™ of $1.39. GuruFocus considers AB Science to be Modestly Undervalued.

Key valuation signals for ABSCF:

  • SpecialCharges:
  • GF Value™: $1.39 vs. price of $1.12 (19.4% below fair value)
  • GF Score™: 60/100 with 11 warning signs

No single metric tells the full story. See the ABSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AB Science Business Description

Other Exchanges 0Q77:UKAB:FranceA8D:Germany
Address 3, Avenue George V, Paris, FRA, 75008
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
60GF Score

Get the complete analysis for ABSCF

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12
Price
$1.39
GF Value